Business Context and Reporting Period
Pasithea Therapeutics Corp. filed this Form 8-K on June 23, 2022, reporting the results of its 2022 Annual Meeting of Shareholders held the same day. The company is a Delaware corporation listed on Nasdaq under KTTA and KTTAW.
Meeting Results and Key Metrics
- At the May 3, 2022 record date, the company had 22,858,371 shares of common stock issued and outstanding.
- All five director nominees were elected for one-year terms:
- Dr. Tiago Reis Marques: 5,792,046 votes for; 2,073,308 abstentions.
- Dr. Yassine Bendiabdallah: 5,792,534 votes for; 2,072,820 abstentions.
- Prof. Lawrence Steinman: 5,769,723 votes for; 2,095,631 abstentions.
- Simon Dumesnil: 5,779,224 votes for; 2,086,130 abstentions.
- Dr. Emer Leahy: 5,813,102 votes for; 2,052,252 abstentions.
- Shareholders ratified Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022: 10,751,385 votes for, 1,078,159 against, and 15,560 abstentions.
Financial Information and Material Changes
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating and financial metrics. It also does not report a material change versus a prior comparable period.
Outlook, Risks, and Unusual Items
The filing contains no new management guidance, outlook, risk disclosures, contingencies, or unusual financial items. The principal reported corporate actions were the election of the board and auditor ratification.
Investor Verification Items
- Verify the final composition and one-year terms of the board of directors.
- Confirm the appointment of Marcum LLP for the fiscal year ending December 31, 2022.
- Review subsequent filings for financial results, financing activity, liquidity, and any changes in corporate strategy or governance.
- Note that the filing text does not clearly provide total shares present or voting percentages.